Healthstream (HSTM) Research & Development (2010 - 2026)

Healthstream (HSTM) has 17 years of Research & Development data on file, last reported at $13.0 million in Q1 2026.

• On a quarterly basis, Research & Development rose 7.58% year-over-year to $13.0 million in Q1 2026; TTM through Mar 2026 was $50.0 million, a 6.07% increase from a year earlier, with the FY2025 full-year figure at $49.4 million, up 4.73% from the prior year.
• Research & Development for Q1 2026 stood at $13.0 million, down from $13.2 million in the prior quarter.
• Over the last five years, Research & Development for HSTM reached as high as $13.2 million in Q4 2025 and fell as low as $10.4 million in Q1 2022.
• Historically, Research & Development has averaged $11.7 million across 5 years, with a median of $11.7 million in 2023.
• Across the five-year window, Research & Development dropped 9.81% in 2022 and grew 20.19% in 2025, its largest moves.
• Year by year, Research & Development stood at $11.7 million in 2022, then retreated by 2.2% to $11.4 million in 2023, then decreased by 4.11% to $11.0 million in 2024, then climbed by 20.19% to $13.2 million in 2025, then slipped by 1.53% to $13.0 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $13.0 million in Q1 2026, $13.2 million in Q4 2025, and $12.1 million in Q3 2025.